10. Antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa in Bach Mai Hospital
Main Article Content
Abstract
A total of 104 strains of P. aeruginosa collected from Bach Mai hospital between 2020 and 2021 were tested for susceptibility to ceftolozane/tazobactam using Etest strips. The MIC values of ceftolozane/tazobactam ranged from 0.25 µg/ml to 256 µg/ml. Overall susceptibility to ceftolozane/tazobactam in P. aeruginosa isolates was 63%, MIC50 was 0.5 µg/ml and MIC90 was 256 µg/ml. Susceptibility to ceftolozane/tazobactam in carbapenem-resistant carbapenemase-producing and non-carbapenemase-producing Pseudomonas aeruginosa isolates were 18% and 71%, respectively.
Article Details
Keywords
P. aeruginosa, ceftolozane/tazobactam
References
2.. Robert A Bonomo, Dora Szabo. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43:S49-56. doi: 10.1086/504477
3.. Juan C, Zamorano L, Pérez JL, et al. Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant Pseudomonas aeruginosa Clinical Strains. Antimicrob Agents Chemother. 2010;54(2):846-851. doi: 10.1128/AAC.00834-09
4.. Hong MC, Hsu DI, Bounthavong M. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination. Infect Drug Resist. 2013;6:215-223. doi: 10.2147/IDR.S36140
5.. Wi YM, Greenwood-Quaintance KE, Schuetz AN, et al. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms. Antimicrob Agents Chemother. 2017;62(1). doi: 10.1128/AAC.01970-17
6. Medscape. Zerbaxa (ceftolozane/tazobactam) dosing, indications, interactions, adverse effects, and more. Accessed May 13, 2023. https://reference.medscape.com/drug/zerbaxa-ceftolozane-tazobactam-999969
7. Clinical & Laboratory Standards Institute. CLSI M100 Ed30 Performance Standards for Antimicrobial Susceptibility Testing. https://clsi.org/standards/products/microbiology/documents/m100/
8. SibylleH.Lob. In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019. J Glob Antimicrob Resist. 2022;29:527-533. doi:10.1016/j.jgar.2021.11.011
9. Pfaller M, Shortridge D, Chen WT, et al. Ceftolozane/Tazobactam Activity Against Drug-Resistant Pseudomonas aeruginosa and Enterobacterales Causing Healthcare-Associated Infections in Eight Asian Countries: Report from an Antimicrobial Surveillance Program (2016-2018). Infect Drug Resist. 2022;15:6739-6753. doi:10.2147/IDR.S387097
10. Lee YL, Ko WC, Hsueh PR. Geographic Patterns of Carbapenem-Resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015–2019. Antimicrob Agents Chemother. 66(2):e02000-21. doi:10.1128/AAC.02000-21
11. Nguyễn Thị Thanh Mai. Phenotypic prevalence of resistance to carbapenems, colistin and genes encoding carbapenemase in Pseudomonas aeruginosa. MedPharmRes. 2021;5(1):18-22.
12. Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15-21. doi:10.1177/2049936115621709